Wedbush Bullish on Black Diamond Therapeutics (BDTX) Following Progress in Silevertinib Program
Corroborated by 2 sources from 2 publishers
ushealth1d ago
TL;DR
Wedbush upgrades Rezolute stock rating on FDA feedback Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) is on our list of the top 10 stocks under $5 that could triple. As its focus remains on precision oncology, Black Diamond Therapeutics, Inc.